The University of Chicago Comprehensive Cancer Center (UCCCC) is submitting this competitive renewal application for its Cancer Center Support Grant for Years 38-42. The mission of the UCCCC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer. Our cancer research programs emphasize translational and interdisciplinary research, and we pursue this goal by promoting collaboration among a diverse and dedicated team of outstanding basic, translational, clinical, and population researchers. The 210 members of the UCCCC are organized into six established programs, all with a translational focus (Molecular Mechanisms of Cancer;Hematopoiesis and Hematologic Malignancies;Immunology and Cancer;Pharmacogenomics and Experimental Therapeutics;Advanced Imaging;and Cancer Prevention and Control). Clinical research is a major focus of multidisciplinary activity at the UCCCC. In 2011, 876 individual patients were accrued to therapeutic protocols supported, in part, by NCI cooperative agreements and contracts to conduct Phase I, Phase II, and Phase III clinical trials. The UCCCC is a full member of the Alliance (formerly members of Cancer and Leukemia Group B and American College of Surgeons Oncology Group), the Gynecologic Oncology Group, and the Children's Oncology Group, and participates in the Radiation Therapy Oncology Group, and National Surgical Adjuvant Breast and Bowel Program studies. Funds are requested in this application for Senior Leaders and Program Leaders, Planning and Evaluation, Developmental Funds, Administration, Protocol-Specific Research, the Protocol Review and Monitoring System, Staff Investigators, and 11 shared resources (Biostatistics;Cancer Clinical Trials Office;Cytometry and Antibody Technology;Genomics;Human Immunologic Monitoring and cGMP;Human Tissue Resource Center;Image Computing, Analysis, and Repository;Integrated Microscopy;Integrated Small Animal Imaging Research Resource;Pharmacology;and Transgenic Mouse/Embryonic Stem Cell Facilities). In the period since the last review (2008-2011), the UCCCC has increased its peer-reviewed funding by 27% to $68.9 million in direct costs (NCI funding has increased by 17% from $18 to $21 million in direct costs), and contributed 1,850 peer-reviewed publications. Through an in-depth institutional review and multi-faceted strategic planning process, the UCCCC now has new and strong institutional commitments, and a stable and experienced leadership team, and has developed and implemented a comprehensive strategic plan, and restructured its Research Programs.

Public Health Relevance

The mission of the UCCCC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer. In addition, we provide education and training for basic scientists, physicians, and clinical investigators, and local health professionals, as well as develop and implement community-based cancer education and outreach programs. Our mission is fulfilled in an environment that values diversity, the development of the next generation of physicians and scientists, and delivering comprehensive and compassionate patient care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014599-39S1
Application #
8788972
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-09-01
Project End
2018-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
39
Fiscal Year
2014
Total Cost
$74,999
Indirect Cost
$27,531
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977

Showing the most recent 10 out of 668 publications